About Us

MDI Therapeutics has assembled a management team with a combination of drug development, manufacturing and basic research expertise in serpin biology. An early stage pipeline has been established, with a focused approach to serpin targeting, initially interrogating pathways associated with fibrosis, inflammation, and thrombosis. Key intellectual property has been licensed, and laboratory space secured. Our goal is to become the global leader in treating disorders of serpin dysregulation through leveraging our extensive knowledge of serpin biology in the development of novel biologic and small molecule therapeutics.